Arrowhead Pharmaceuticals, Inc. (ARWR) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology.
Is Arrowhead Pharmaceuticals, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) trades at $59.90 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Arrowhead Pharmaceuticals, Inc.
Market cap $8B · 52 weeks $38 – $90 (33 % below the high) · P/E no earnings · Dividend none · Next earnings November 24, 2026 · expected EPS $-1.52 · Closing price, Oct 30 · accounts published Aug 4.
- Valuation: P/Sales 4.6× (no earnings).
- Balance sheet: Grey zone (watch).
- Earnings: 2 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 7.6 %, fails.
- Market cap / Cash 8.7×, fails.
- Annual cash burn $1.34, passes.
- Total Debt 0.5×, passes.
Against its peers (reference peers) — Arrowhead Pharmaceuticals, Inc.: P/E —; EV/EBITDA —; ROIC -12.1 %; $8.5B. Alnylam Pharmaceuticals, Inc. (P/E 8.3×; EV/EBITDA 18.3×; ROIC 15.4 %; $22.1B), TG Therapeutics, Inc. (P/E 22.3×; EV/EBITDA 67.5×; ROIC 9.9 %; $9.4B), Protagonist Therapeutics, Inc. (P/E 140×; EV/EBITDA 104×; ROIC 6.7 %; $9.4B).
Profitability
| Return on Equity | -60.54% |
| Return on Invested Capital | -12.12% |
| Return on Assets | -15.15% |
| Gross Margin | 100.00% |
| Operating Margin | -33.82% |
| Net Margin | -47.79% |
Financial Health
| Debt / Equity | 1.86 |
| Current Ratio | 5.90 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 2.98 |
Price Performance
| 1 month | -7.55% |
| 3 months | -29.24% |
| Year-to-date | -9.78% |
| 1 year | +41.31% |
| 3 years | +132.26% |
| 5 years | -15.62% |
| 10 years | +925.68% |
Related companies: ALNY · IONS · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ARWR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks